Gut microbiota and stroke: New avenues to improve prevention and outcome
European Journal of Neurology · 2023-11 · 30 (11) · 3595-3604
DOI: 10.1111/ene.15770 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 06.04.2023. Verfasst von Paul Clottes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Stroke Department, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Stroke, Dysbiosis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Despite major recent therapeutic advances, stroke remains a leading cause of disability and death. Consequently, new therapeutic targets need to be found to improve stroke outcome. The deleterious role of gut microbiota alteration (often mentioned as “dysbiosis”) on cardiovascular diseases, including stroke and its risk factors, has been increasingly recognized. Gut microbiota metabolites, such as trimethylamine‐ N ‐oxide, short chain fatty acids and tryptophan, play a key role. Evidence of a link between alteration of the gut microbiota and cardiovascular risk factors exists, with a possible causality link supported by several preclinical studies. Gut microbiota alteration also seems to be implicated at the acute phase of stroke, with observational studies showing more non‐neurological complications, higher infarct size and worse clinical outcome in stroke patients with altered microbiota. Microbiota targeted strategies have been developed, including prebiotics/probiotics, fecal microbiota transplantation, short chain fatty acid and trimethylamine‐ N ‐oxide inhibitors. Research teams have been using different time windows and end‐points for their studies, with various results. Considering the available evidence, it is believed that studies focusing on microbiota‐targeted strategies in association with conventional stroke care should be conducted. Such strategies should be considered according to three therapeutic time windows: first, at the pre‐stroke (primary prevention) or post‐stroke (secondary prevention) phases, to enhance the control of cardiovascular risk factors; secondly, at the acute phase of stroke, to limit the infarct size and the systemic complications and enhance the overall clinical outcome; thirdly, at the subacute phase of stroke, to prevent stroke recurrence and promote neurological recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stroke Department, Hospices Civils de Lyon, Lyon, France.
- CarMeN Laboratoire, INSERM, INRAER, Univ Lyon, Université Claude Bernard Lyon 1, Bron, France.
- Hospices Civils de Lyon, Lyon, France.
- Université Claude Bernard Lyon 1, Lyon, France.
- Tumor Escape Resistance and Immunity Department, Cancer Research Center of Lyon (CRCL), Inserm U1052, CNRS UMR 5286, Lyon, France.
- French Fecal Transplant Group, Lyon, France.
ORCID-Profile: Paul Clottes, Laura Mechtouff
Zitieren
APA
Clottes, P., Benech, N., Dumot, C., Jarraud, S., Vidal, H., & Mechtouff, L. (2023). Gut microbiota and stroke: New avenues to improve prevention and outcome. European Journal of Neurology, 30(11), 3595-3604. https://doi.org/10.1111/ene.15770
Vancouver
Clottes P, Benech N, Dumot C, Jarraud S, Vidal H, Mechtouff L. Gut microbiota and stroke: New avenues to improve prevention and outcome. European Journal of Neurology. 2023;30(11):3595-3604. doi:10.1111/ene.15770
BibTeX
@article{Clottes2023,
author = {Clottes, Paul and Benech, Nicolas and Dumot, Chloé and Jarraud, Sophie and Vidal, Hubert and Mechtouff, Laura},
title = {Gut microbiota and stroke: New avenues to improve prevention and outcome},
journal = {European Journal of Neurology},
year = {2023},
volume = {30},
number = {11},
pages = {3595--3604},
doi = {10.1111/ene.15770}
}
EUVIMED